| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/11/2011 | CN101121677B Agmatine sulfate dihydrate and medical use thereof |
| 05/10/2011 | US7939670 Nociceptin analogs |
| 05/10/2011 | US7939639 Functional role of adrenomedullin (AM) and the gene related product (PAMP) in human pathology and physiology |
| 05/10/2011 | US7939549 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof |
| 05/10/2011 | US7939525 Conjugated psychotropic drugs and uses thereof |
| 05/10/2011 | US7939522 Dosage formulations for acetylcholinesterase inhibitors |
| 05/10/2011 | US7939520 Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
| 05/10/2011 | US7939493 Peptide inhibitors of protein kinase C |
| 05/10/2011 | US7939490 TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| 05/10/2011 | US7939116 Sulfur-containing proanthocyanidin oligomer composition and production method thereof |
| 05/10/2011 | US7939102 Controlled release formulation of lamotrigine |
| 05/10/2011 | US7938641 Extrusion die |
| 05/10/2011 | CA2485535C Modified release pharmaceutical formulation |
| 05/10/2011 | CA2483105C Autoimmune conditions and nadph oxidase defects |
| 05/10/2011 | CA2478335C Amino-methyl substituted tetracycline compounds |
| 05/10/2011 | CA2477004C Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| 05/10/2011 | CA2475498C Piperidine derivative and pharmaceutical composition comprising the same as active ingredient |
| 05/10/2011 | CA2463102C Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors |
| 05/10/2011 | CA2457057C Compositions and methods for treating neurodegenerative diseases |
| 05/10/2011 | CA2451279C Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments |
| 05/10/2011 | CA2436935C Serine protease inhibitors |
| 05/10/2011 | CA2433158C Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor |
| 05/10/2011 | CA2419633C Substituted imidazoles as tafia inhibitors |
| 05/10/2011 | CA2418815C Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative |
| 05/10/2011 | CA2377373C Nitric oxide donors for inducing neurogenesis |
| 05/10/2011 | CA2361249C Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| 05/10/2011 | CA2248016C Direct molecular diagnosis of friedreich ataxia |
| 05/05/2011 | WO2011054001A2 Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
| 05/05/2011 | WO2011053829A1 Dosing regimen associated with long-acting injectable paliperidone esters |
| 05/05/2011 | WO2011053825A2 Compositions and methods for the treatment or prevention of mitochondrial diseases |
| 05/05/2011 | WO2011053821A1 Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| 05/05/2011 | WO2011053792A2 Methods and compositions for sustained delivery of drugs |
| 05/05/2011 | WO2011053705A1 Pyrimidine compounds as delta opioid receptor modulators |
| 05/05/2011 | WO2011053701A1 Phenoxy-substituted pyrimidines as opioid receptor modulators |
| 05/05/2011 | WO2011053696A1 Pyrazines as delta opioid receptor modulators |
| 05/05/2011 | WO2011053675A2 Improved neurturin molecules |
| 05/05/2011 | WO2011053636A1 Methods of treating psychiatric or neurological disorders with mglur antagonists |
| 05/05/2011 | WO2011053511A1 Heteroaryl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists |
| 05/05/2011 | WO2011053510A1 Heterocyclyl substituted arylindenopy-rimidines and their use as highly selective adenosine a2a receptor antagonists |
| 05/05/2011 | WO2011053509A1 Aryl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists |
| 05/05/2011 | WO2011053508A1 ALKYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS |
| 05/05/2011 | WO2011053507A1 2-amino-9-[4-(4-methoxy-phenoxy) - piperid in -1-yl] -4-phenyl-indeno [1,2-d] pyrimidin -5 -one and its use as a highly selective adenosine a2a receptor antagonist |
| 05/05/2011 | WO2011053292A1 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| 05/05/2011 | WO2011053191A1 Agent for treating stress-related diseases and disorders in humans and animals, and treatment and/or prevention method using said agent |
| 05/05/2011 | WO2011052968A2 Composition for preventing or treating degenerative neurological disorder, containing oleanonic acid |
| 05/05/2011 | WO2011052888A2 (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition containing same as active ingredients for the diagnosis or treatment of neurodegenerative brain diseases |
| 05/05/2011 | WO2011052753A1 Antibody binding to mansc1 protein and having anticancer activity |
| 05/05/2011 | WO2011052668A1 Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood |
| 05/05/2011 | WO2011051858A1 Imidazole derivatives as casein kinase inhibitors |
| 05/05/2011 | WO2011051478A1 Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| 05/05/2011 | WO2011051423A1 Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy |
| 05/05/2011 | WO2011051375A1 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them |
| 05/05/2011 | WO2011051342A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| 05/05/2011 | WO2011050864A1 New compounds for the treatment of diseases related to protein misfolding |
| 05/05/2011 | WO2011050742A1 New crystalline forms of agomelatine and preparation methods thereof |
| 05/05/2011 | WO2011050728A1 Stable composition of rasagiline |
| 05/05/2011 | WO2011050590A1 Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof |
| 05/05/2011 | WO2011050481A1 New eremophilane sesquiterpene lactones from senecio jacobaea |
| 05/05/2011 | WO2011050397A1 Novel enteric combination therapy |
| 05/05/2011 | WO2011021221A3 Compositions for spinal cord injury |
| 05/05/2011 | WO2011009873A3 New form of the aminoindan mesylate derivative rasaginline mesylate |
| 05/05/2011 | WO2010031248A8 Thiazolium salt compound and the use of treating the protein aging disease |
| 05/05/2011 | US20110107443 Novel protein transduction domains derived from secretory leukocyte protease inhibitor |
| 05/05/2011 | US20110106006 Implantable device for long-term delivery of drugs |
| 05/05/2011 | US20110105998 Systems, methods and compositions for optical stimulation of target cells |
| 05/05/2011 | US20110105748 Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds |
| 05/05/2011 | US20110105626 Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases |
| 05/05/2011 | US20110105622 Pharmaceutical composition containing glur2-lacking ampar antagonist for preventing or treating psychiatric illnesses |
| 05/05/2011 | US20110105621 Method of reducing brain cell damage, inflammation or death |
| 05/05/2011 | US20110105619 Amorphous bupropion hydrobromide and preparation thereof |
| 05/05/2011 | US20110105610 Phospholipase A2 Inhibitors and their Use in Treating Neurological Injury and Disease |
| 05/05/2011 | US20110105607 Lipophilic diesters of chelating agent for inhibition of enzyme activity |
| 05/05/2011 | US20110105603 Compositions and methods for treating beta-amyloid related diseases |
| 05/05/2011 | US20110105599 Therapeutic or preventive agents for ischemic neuropathy |
| 05/05/2011 | US20110105594 Palatable nutritional composition comprising a nucleotide and/or a nucleoside and a taste masking agent |
| 05/05/2011 | US20110105587 Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases |
| 05/05/2011 | US20110105584 Rtp80il sirna compounds and methods of use thereof |
| 05/05/2011 | US20110105578 Substituted Imidazole Derivatives And Methods Of Use Thereof |
| 05/05/2011 | US20110105573 Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof |
| 05/05/2011 | US20110105571 Opioid Receptor Antagonists |
| 05/05/2011 | US20110105570 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
| 05/05/2011 | US20110105569 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
| 05/05/2011 | US20110105560 Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes |
| 05/05/2011 | US20110105556 Tris-quarternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors |
| 05/05/2011 | US20110105555 Substituted n-imidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands |
| 05/05/2011 | US20110105553 New classes of gabaa/bzr ligands |
| 05/05/2011 | US20110105551 Analgesics for nasal administration |
| 05/05/2011 | US20110105549 Branched 3- and 6-substituted quinolines as cgrp receptors antagonists |
| 05/05/2011 | US20110105548 N-aryl diazaspirocyclic compounds and methods of preparation and use thereof |
| 05/05/2011 | US20110105543 Novel triaryl derivatives useful as modulators of nicotinic acetylcholine receptors |
| 05/05/2011 | US20110105541 ALKYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS |
| 05/05/2011 | US20110105540 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST |
| 05/05/2011 | US20110105538 Drug response markers |
| 05/05/2011 | US20110105537 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors |
| 05/05/2011 | US20110105536 Dosing regimen associated with long-acting injectable paliperidone esters |
| 05/05/2011 | US20110105533 Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof |
| 05/05/2011 | US20110105528 1-(7-(hexahydropyrrolo [3, 4-c] pyrrol-2 (1h)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3) |
| 05/05/2011 | US20110105527 Pyrazines as delta opioid receptor modulators |
| 05/05/2011 | US20110105526 Selective subtype alpha 2 adrenergic agents and methods for use thereof |
| 05/05/2011 | US20110105524 Cysteine protease inhibitors |